Urinary incontinence in women, specifically stress and mixed urinary incontinence.. Unspecified urinary incontinence
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will consist of women with urinary incontinence who will undergo electromagnetic stimulation (EM) therapy for 3 months, with sessions three t
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women aged between 20 and 45 years Diagnosed with urinary incontinence Willing and able to provide informed consent Able to attend all study visits and comply with study procedures No prior treatment with electromagnetic stimulation for urinary incontinence
Exclusion criteria
Exclusion criteria: Women with a history of pelvic surgery in the last 6 months Pregnant or breastfeeding women Women with neurological disorders affecting bladder function Presence of urinary tract infection at baseline Use of medications that affect bladder control Implanted pacemakers or metallic implants in the pelvic area Severe cognitive impairment or psychiatric disorders preventing consent or participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes include the 20-minute pad test, 24-hour pad test, voided urine volume, daily urination frequency, and presence of urine leakage. These outcomes will be compared between the two groups. Timepoint: Patients will be assessed at baseline (before intervention), and then at 3 months and 6 months after the treatment. Method of measurement: The primary outcome variables will be measured using the following tools: Urinary leakage will be assessed by the 20-minute and 24-hour pad test. Urine volume and frequency of urination will be recorded using patient self-monitoring and clinical evaluation. The presence of urinary incontinence will be evaluated based on clinical examination and patient reports. Quality of life will be measured using the International Consultation on Incontinence Questionnaire (ICIQ). Vaginal muscle contraction strength will be assessed using the Circumvaginal Muscle (CVM) scoring system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes include patient quality of life measured by the International Consultation on Incontinence Questionnaire (ICIQ) and the average circumvaginal muscle (CVM) contraction strength score. Timepoint: Patients will be assessed at baseline (before intervention), and then at 3 months and 6 months after the treatment. Method of measurement: International Consultation on Incontinence Questionnaire (ICIQ) and the average circumvaginal muscle (CVM). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Maryam Karamali
Iran University of Medical Sciences
Outcome results
None listed